Home
About
Overview
Sharing Data
ORCID
Help
History (55)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Tyrosine kinase mutations in human cancer.
See All 55 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tyrosine kinase mutations in human cancer.
Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
View in:
PubMed
subject areas
ErbB Receptors
Humans
Mutation
Neoplasms
Phosphatidylinositol 3-Kinases
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-kit
Proto-Oncogene Proteins c-met
authors with profiles
Ravi Salgia
Ernst Lengyel